Searchable abstracts of presentations at key conferences in endocrinology

ea0037ep194 | Reproduction, endocrine disruptors and signalling | ECE2015

Evaluation of an automatic referral system for inpatients with hyponatraemia: prompt referral leads to active intervention

Mannan Jayamalathy Mannar , Joshi Mamta , Vincent Roy , Sherwood Roy , Jafar-Mohammadi Bahram , Gilbert Jackie , Whitelaw Benjamin , Aylwin Simon

Inpatients with hyponatraemia have a high mortality and longer length of stay. We instituted a system of automatic referral to the endocrinology team where any inpatient with a serum (Na+) ≤125 mmol/l was referred automatically from their biochemical results.Aims: We evaluated the diagnosis, management, and outcome of the patients referred with hyponatraemia over 6 months.Methods: Data were prospectively captured e...

ea0034p424 | Thyroid | SFEBES2014

Evaluation of calcitonin as a screening tool for medullary thyroid carcinoma in patients with nodular thyroid disease

Sivasubramaniyam Sivasujan , Sherwood Roy , Gilbert Jackie

Background and aims: The use of serum calcitonin to screen patients with nodular thyroid disease for medullary thyroid cancer (MTC) remains controversial due to conflicting data regarding its sensitivity, specificity and cost effectiveness. Currently, the use of calcitonin is recommended by the European consensus group but not the American Thyroid Association. We aimed to formally evaluate the utility of calcitonin as a screening tool for MTC in patients presenting to the thyr...

ea0046p10 | (1) | UKINETS2016

Biomarkers for carcinoid heart disease

Basuroy Ron , Ramage John , Sherwood Roy , Srirajaskanthan Rajaventhan

Introduction: Carcinoid heart disease (CHD) develops in patients with small bowel NETs with carcinoid syndrome. Currently NT-proBNP (NTP) is suggested as the best current biomarker to screen for CHD and monitor heart failure. A number of other markers have been investigated for heart failure, however, none of these have been explored in NET patients with CHD or carcinoid syndrome. Galectin-3 (GAL3) promotes fibroblast proliferation and correlates with worse outcomes in heart f...

ea0038p398 | Steroids | SFEBES2015

Discrimination of adrenocortical carcinoma from other adrenal lesions: use of a new 13 steroid serum panel based on LC–MS/MS

Taylor David , Ghataore Lea , Vincent Royce , Sherwood Roy , Whitelaw Ben , Dworakowska Dorota , Schulte Klaus-Martin , Diaz-Cano Salvadore , Lewis Dylan , Aylwin Simon , Taylor Norman

Adrenocortical carcinoma (ACC) is a rare malignancy, but accounts for up to 11% of adrenal masses investigated in referral centres. Diagnosis remains a challenge. Up to two thirds are biochemically inactive, resulting from de facto enzyme deficiencies in the steroid hormone biosynthetic pathways, as shown by urine steroid profiling by gas chromatography-mass spectrometry. Increased metabolites of pathway intermediates in ACC discriminate it from benign adrenal lesions...

ea0031p57 | Clinical practice/governance and case reports | SFEBES2013

Initiation and maintenance of mitotane as adjuvant therapy for adrenocortical cancer: a single centre experience

Whitelaw Benjamin , Mustafa Omar , Coskeran Patsy , Prague Julia , Kordbacheh Tiana , Lewis Dylan , Diaz-Cano Salvador , Sherwood Roy , Gilbert Jackie , McGregor Alan , Aylwin Simon

Background: Mitotane is an adrenolytic chemotherapy, currently accepted as first line adjuvant therapy in adrenocortical carcinoma. Mitotane has a narrow therapeutic window. Serum levels of >14 mg/l are required to achieve a cytotoxic effect and levels of >20 mg/l are potentially toxic. There are two strategies for mitotane initiation: a low-dose regimen (3 g) and a high-dose regimen (increase to 6g/day over 4 days and reduce to 4.5 g/day after 10 days).<p class="...

ea0031p257 | Pituitary | SFEBES2013

Endocrine remission of Cushing's disease after endoscopic trans-sphenoidal surgery: Retrospective review of a single centre experience

Kennard Devon , Whitelaw Ben , Dworakowska Dorota , Thomas Nick , Barazi Sinan , Bullock Peter , King Andrew , Hampton Tim , Sherwood Roy , Buchanan Charles , Gilbert Jackie , McGregor Alan , Aylwin Simon

Background: Cushing’s disease is caused by corticotroph tumours of the pituitary gland and the standard first-line treatment is trans-sphenoidal surgery. Published data from other centres describes post-operative endocrine remission achieved in 50–90% of cases.Table 1 Remission (cortisol <50)Cortisol (50–150 nmol/l)<td alig...

ea0031p107 | Clinical practice/governance and case reports | SFEBES2013

Unusual presentations of adrenocortical tumours

Mustafa Omar , Whitelaw Ben , Jenkins Rebeka , Kordbacheh Tiana , Salaris Paola , Manu Chris , Taylor Norman , Sherwood Roy , Vivian Gill , Lewis Dylan , Schulte Klaus-Martin , Diaz-Cano Salvador , Gilbert Jackie , McGregor Alan , Aylwin Simon

Background: Adrenocortical tumours (adenoma or carcinoma) present in well-recognised ways: hormones excess (Cushing’s, Conn’s, virilisation) or hormonally silent with symptoms of mass effect, or found incidentally on imaging. We present 3 cases of adrenal tumours, referred to our regional adrenal multidisciplinary meeting with unusual presenting features.Case 1: post-menopausal bleeding: A previously well 57-year-old female presented with vagin...